- Home
- KGEI vs IPHA Comparison
KGEI vs IPHA Comparison
Compare KGEI & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KGEI
- IPHA
- Stock Information
- Founded
- KGEI 2008
- IPHA 1999
- Country
- KGEI United States
- IPHA France
- Employees
- KGEI N/A
- IPHA N/A
- Industry
- KGEI
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- KGEI
- IPHA Health Care
- Exchange
- KGEI Nasdaq
- IPHA Nasdaq
- Market Cap
- KGEI 163.1M
- IPHA 160.1M
- IPO Year
- KGEI N/A
- IPHA 2019
- Fundamental
- Price
- KGEI $4.01
- IPHA $1.82
- Analyst Decision
- KGEI Strong Buy
- IPHA Strong Buy
- Analyst Count
- KGEI 1
- IPHA 3
- Target Price
- KGEI $11.00
- IPHA $5.00
- AVG Volume (30 Days)
- KGEI 72.2K
- IPHA 569.3K
- Earning Date
- KGEI 11-12-2025
- IPHA 09-17-2025
- Dividend Yield
- KGEI N/A
- IPHA N/A
- EPS Growth
- KGEI 1.99
- IPHA N/A
- EPS
- KGEI 0.49
- IPHA N/A
- Revenue
- KGEI $60,121,000.00
- IPHA $14,839,695.00
- Revenue This Year
- KGEI $6.94
- IPHA $22.29
- Revenue Next Year
- KGEI $14.53
- IPHA $43.84
- P/E Ratio
- KGEI $8.21
- IPHA N/A
- Revenue Growth
- KGEI 10.00
- IPHA N/A
- 52 Week Low
- KGEI $3.34
- IPHA $1.29
- 52 Week High
- KGEI $9.89
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- KGEI 29.87
- IPHA 43.07
- Support Level
- KGEI $3.87
- IPHA $1.80
- Resistance Level
- KGEI $4.28
- IPHA $2.43
- Average True Range (ATR)
- KGEI 0.16
- IPHA 0.14
- MACD
- KGEI 0.01
- IPHA -0.02
- Stochastic Oscillator
- KGEI 21.74
- IPHA 11.68
About KGEI Kolibri Global Energy Inc. Common stock
Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. The company derives a majority of its revenue from the United States.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.